Roche Holding’s fair value estimate has edged up to about CHF 312 from roughly CHF 305, supported by a slightly higher long term revenue growth outlook of around 1.51% versus about 1.48% previously. With the discount rate steady near 3.86%, this recalibration reflects mounting confidence in Roche’s ability to turn its oncology, ophthalmology, and external innovation efforts into a more durable growth trajectory. Stay tuned to see how you can track these narrative shifts as new trial results, partnerships, and strategic moves feed back into the stock’s evolving valuation story.
Stay updated as the Fair Value for Roche Holding shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Roche Holding.
🐂 Bullish Takeaways
Oppenheimer highlights Roche Pharma’s global rollout of Veeva’s Vault CRM as an expectations and sentiment win, pushing back against concerns that the company might pivot to Salesforce and underscoring disciplined commercial execution.
H.C. Wainwright points to milestone payments and advancing studies in the OpRegen dry-AMD and geographic atrophy program as tangible evidence of progress in Roche partnered innovation, reinforcing the long term growth narrative in ophthalmology.
Guggenheim’s reaction to the successful Phase 3 lidERA trial, which drove a price target increase on Olema to $40 from $20, underlines how Roche’s oncology data can strengthen confidence in the broader SERD mechanism and its own pipeline productivity.
BTIG views Roche’s acquisition of 89bio and related M&A activity as a supportive signal for sector valuations and strategic optionality, suggesting Roche remains an active allocator of capital to external growth drivers.
🐻 Bearish Takeaways
Morgan Stanley’s Sarita Kapila raised the Roche price target only modestly to CHF 255 from CHF 245 while maintaining an Underweight rating, indicating ongoing reservations that the current share price may already discount much of the anticipated growth.
Jefferies flags mixed Phase 3 data for Satralizumab in thyroid eye disease as a setback that eases competitive pressure for Viridian, reflecting execution risk in parts of Roche’s pipeline and reminding investors that not all late stage assets will translate into incremental value.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
SWX:ROG Community Fair Values as at Dec 2025
Roche secured conditional European Commission approval for subcutaneous Lunsumio in relapsed or refractory follicular lymphoma after at least two prior systemic therapies, introducing a 1 minute injection option that could replace lengthy intravenous infusions while supporting deeper, durable remissions.
Positive phase III results from the lidERA and evERA breast cancer trials showed oral SERD giredestrant improved disease free and progression free survival in early stage and metastatic ER positive, HER2 negative breast cancer, bolstering Roche’s competitive standing in hormone receptor positive disease.
Phase III studies of BTK inhibitor fenebrutinib in relapsing and primary progressive multiple sclerosis met key endpoints, with data indicating superiority to teriflunomide and to Ocrevus on disability measures, strengthening Roche’s long term neurology growth story.
Regulators cleared multiple new indications for Gazyva or Gazyvaro in lupus nephritis, systemic lupus erythematosus and idiopathic nephrotic syndrome, while industry coverage highlighted a multibillion-dollar wave of investment in PD-1 or PD-L1 plus VEGF based bispecifics, including programs building on Roche’s Avastin, as investors seek next generation immuno oncology combinations despite limited overall survival data so far.
Story continues
Fair Value Estimate has risen slightly to about CHF 312 from roughly CHF 305, reflecting modestly more constructive long term assumptions.
Discount Rate is effectively unchanged at around 3.86%, indicating a stable risk and return framework in the valuation model.
Revenue Growth has increased slightly, with the long term annual growth assumption moving from about 1.48% to roughly 1.51%.
Net Profit Margin has risen modestly, with the steady state margin assumption increasing from about 24.30% to roughly 24.66%.
Future P/E multiple has inched higher to about 17.0x from roughly 16.9x, indicating a marginally stronger outlook for Roche’s earnings power.
Narratives are shared stories that connect Roche Holding’s business reality to the numbers, turning your view of its pipeline, revenues, earnings, and margins into a clear fair value. On Simply Wall St’s Community page, millions of investors use Narratives as an accessible tool that ties a company’s story to forecasts and a fair value, then compares that to today’s price to guide buy or sell decisions. As news, trials, and earnings change, these Narratives update dynamically so your thesis always reflects the latest information.
Head over to the Simply Wall St Community and follow the Narrative on Roche Holding to stay on top of:
How expanding diagnostics platforms and high value biologics support long term revenue growth and more resilient cash flows.
Whether automation, AI, and CHF 3b of planned cost savings by 2030 can lift margins and justify a forward P/E near 17x.
How patent expiries, China pricing pressure, and trial risks could derail forecasts and shift Roche’s fair value versus today’s price.
Read the full Roche Holding Narrative on Simply Wall St to see how these drivers roll up into forecasts and fair value, and decide whether the current price still offers upside or not.
Curious how numbers become stories that shape markets? Explore Community Narratives
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROG.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com